These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25510390)

  • 41. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.
    Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT
    Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human papillomavirus vaccines: WHO position paper, October 2014.
    Wkly Epidemiol Rec; 2014 Oct; 89(43):465-91. PubMed ID: 25346960
    [No Abstract]   [Full Text] [Related]  

  • 44. Human papillomavirus vaccines. WHO position paper.
    Wkly Epidemiol Rec; 2009 Apr; 84(15):118-31. PubMed ID: 19360985
    [No Abstract]   [Full Text] [Related]  

  • 45. HPV vaccine recommendations.
    Committee on Infectious Diseases
    Pediatrics; 2012 Mar; 129(3):602-5. PubMed ID: 22371460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus vaccines: an update for gynecologists.
    Ault KA
    Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
    Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
    Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
    Grant LA; Dunne EF; Chesson H; Markowitz LE
    Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human papillomavirus vaccine update.
    Gilmer LS
    Prim Care; 2015 Mar; 42(1):17-32. PubMed ID: 25634702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus vaccine introduction--the first five years.
    Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
    Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus: current status and issues of vaccination.
    Malik H; Khan FH; Ahsan H
    Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Developing evidence-based immunization recommendations and GRADE.
    Duclos P; Durrheim DN; Reingold AL; Bhutta ZA; Vannice K; Rees H
    Vaccine; 2012 Dec; 31(1):12-9. PubMed ID: 22391401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.
    Laprise JF; Markowitz LE; Chesson HW; Drolet M; Brisson M
    J Infect Dis; 2016 Sep; 214(5):685-8. PubMed ID: 27234416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discrepancies in the evaluation of the safety of the human papillomavirus vaccine.
    Cervantes JL; Doan AH
    Mem Inst Oswaldo Cruz; 2018; 113(8):e180063. PubMed ID: 29846395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Up to date: comprehensive knowledge of human papillomavirus.
    Park JS; Hur S
    Expert Rev Vaccines; 2013 Apr; 12(4):353-5. PubMed ID: 23560916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.